Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2021-10-28 Regulatory Filings
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content specifically addresses a Regulation FD Disclosure correcting a misstated grant amount mentioned in a public interview by a board member. There are no financial statements or detailed financial data presented, nor is this an announcement of an annual or quarterly report. The document is short (3288 characters) and serves as a regulatory disclosure of a specific event rather than a full report. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2021-10-28 English
Regulatory Filings 2021
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes the commencement of patient recruitment for a clinical trial, which is an event update rather than a financial report or detailed management discussion. The document is relatively short (3,678 characters) and does not contain financial statements or detailed analysis. It is not an Annual Report, Earnings Release, or Interim Report. It is also not a proxy, voting result, or governance document. The Form 8-K is a regulatory filing used to disclose material events promptly. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-10-04 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-09-03 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Q3 2021
2021-09-01 English
Director's Dealing 2021
Director's Dealing
2021-07-28 English
Director's Dealing 2021
Director's Dealing
2021-07-27 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.